title: Non-pegylated liposomal doxorubicin (Myocet®) in patients with poor-risk aggressive B-cell non-Hodgkin lymphoma.
abstract: The incidence of non-Hodgkin lymphomas increases with age. Non-pegylated liposomal formulations of doxorubicin (Myocet®) reduce systemic and cardiac toxicity especially in the elderly, who often have cardiac diseases. We treated 80 patients (mean age 70.9 years) with poor-risk diffuse large B-cell lymphoma with the R-COMP 21 regimen (Myocet® 50 mg/m(2), cyclophosphamide 750 mg/m(2), vincristine 1.4 mg/m(2), rituximab 375 mg/m(2), prednisone 100 mg/day). In all, 82.5% and 13.7% patients showed complete and partial responses, respectively. Sixty-two of the 80 patients are alive and disease-free (77.5%), while 3/80 are alive with active disease and 15 patients (18.7%) have died (median follow-up: 31 months). The estimated probability of overall survival at 12/24 months from admission was 93.5/87.3%, respectively. There were no therapy-related cardiac events and the ejection fraction improved (from 51.6 ± 6.9% to 54.2 ± 3.9%). Grade 3-4 neutropenia occurred in 22% of patients. We concluded that Myocet® shows both efficacy and tolerability, mainly at the cardiac level.
authors: Hematology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy. matteodellolio@tiscali.it
authors: Matteo
authors: M
authors: Dell'Olio
authors: Rosario Potito
authors: RP
authors: Scalzulli
authors: Grazia
authors: G
authors: Sanpaolo
authors: Michele
authors: M
authors: Nobile
authors: Francesco Saverio
authors: FS
authors: Mantuano
authors: Antonio
authors: A
authors: La Sala
authors: Giovanni
authors: G
authors: D'Arena
authors: Eustachio
authors: E
authors: Miraglia
authors: Anna
authors: A
authors: Lucania
authors: Lucia
authors: L
authors: Mastrullo
authors: Cascavilla
authors: C
authors: Nicola